Get Permission Najmuddin, Almishy, Alhazmi, Jundus, Gharawi, and Safeena: Covid tongue: A new indicator of COVID-19 infection-A case report


Introduction

A handful cases of anonymous viral pneumonia were registered in China in December 2019.1, 2, 3, 4 The pathogen, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), was isolated from infected patient’s lower respiratory tract samples, and was referred to as Coronavirus Disease 2019 (COVID-19). 5, 6 It has reached a high rate of infectivity with worldwide estimates of approximately 205,338,159 cases and 4333094 deaths by November 2020. 7, 8

Transmission of SARS-CoV-2 may take place during the time of incubation period which might be as long as 14 days. 5, 9 Asymptomatic individuals (or peoples within the incubation period) has also been identified as potential carriers; but, the level to which this takes place remains uncertain. 5, 9 It is presumed to transmit by direct person-to-person in proximity of about 2 meter, a range at which an affected individual's respiratory droplets might spread to other people who do not have suitable barriers on coughing, sneezing or speaking. 1, 2, 10, 11, 12, 13, 14, 15 Another route of transmission occurs indirectly when people comes in contact with the salivary droplets which land on various objects, such as the ground and the soil. 10, 13, 16, 17

There is a varied clinical range of COVID-19 infection, which depends on the host immune reaction. Fever, fatigue, malaise, cough, dyspnea, loss of taste and smell are the most common symptoms. Sever symptoms include advanced pneumonia with respiratory arrest and even death.1, 5, 7, 11, 18, 19, 20 Elderly patients with or without devastating conditions such as cardiovascular disease, high blood pressure or diabetes are more likely to develop serious infections with higher mortality rates. 1, 3, 7, 11, 21 In Italy, some authors reported cases of dermatological involvement in patients with SARS-CoV-2 infection. Since then many studies have identified dermatological involvement, including lesions ranging from hand and feet affectation in adolescents to vasculitis, rash, urticaria, and varicella-like lesions. 5, 7, 12

This strain of coronavirus, recently referred to as the hit and run virus, certainly modifies the immune system, triggering distinct changes in response reactions that can act against the host, resulting in autoimmune damage. 12, 13 As far as oral manifestations are concerned the question has to be asked whether this strain has specific abilities to pass through oro-pharyngeal epithelial barriers. 12 Bacterial/fungal coinfection is a proposed etiological hypothesis for oral manifestations linked to COVID-19 that may cause over-prescription of broad-spectrum antibiotics for patients with COVID-19, particularly for those who undergo a longer infection course. 22 The prevalence and effect of bacterial and fungal co-infections has still not been studied, especially in patients with acute respiratory distress syndrome, among various factors contributing to morbidity and mortality in COVID-19 patients. 23

So far, insufficient importance has been given to the prevalence of fungal infections in patients infected with COVID-19 who may experience lymphocytopaenia, hospitalization in intensive care unit (ICU), broad-spectrum antibiotic and corticosteroid usage, intubation, cytokine storms, and possessing chronic illness which make them seriously immunocompromised. 23, 24, 25, 26, 27, 28

Here, we present a case associated with oral lesions manifested by this virus. Due to the state of alarm declared on 21 March, we were not able to examine her in our clinic, but we had the possibility of video consultations.

Case Report

A 72-years old female patient was admitted to the hospital complaining of loss of sensation and movement over the right of the body. CT scan showed Cerebrovascular accident (CVA) on the left side of her brain. Very next day of admission she developed dyspnea, with high temperature and fluctuating oxygen level. She was shifted to isolation room suspecting COVID-19 infection. A PCR test was performed on the sample obtained from the nasal swab, which was negative. Patient was discharged but after 6 days she developed severe diarrhea, loss of appetite and vomiting. Chest x-ray revealed bilateral multifocal alveolar opacities. Suspecting COVID-19 another PCR test was performed on the sample obtained from the nasal swab which was positive. Patient had a history of cardiac problem, hypertension and diabetes. She also gave a history of stroke 3 years ago.

She developed white to whitish yellow creamy plaque like lesions resembling milk curds or cottage cheese over the dorsal surface of tongue.(Figure 1) It was scrappable leaving behind erythematous bleeding surface. Topical nystatine was applied which lead to the resolution of lesion in 4 days.

Figure 1
https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/81c7f8c2-bfe3-4842-bdb8-2bfaac91a60fimage1.png

Discussion

At the onset of the COVID-19 disease outbreak, the absence of oral participation was thought to be a distinctive characteristic of COVID-19 exanthema compared to other viral exanthemas. SARS-CoV-2 has been identified from patient saliva and the reverse transcriptase-polymerase chain reaction (RT-PCR) from saliva has been shown to be far more sensitive compared to the nasopharyngeal examination.

Essentially, SARS-CoV-2 uses angiotensin converting enzyme 2 (ACE2) receptors to enter cells, primarily those of the lower respiratory system. 11, 13, 29, 30  SARS-CoV-2 may infect nasal and oral mucosal cells along its path to lower respiratory system, which may explain the incidence of odor and taste dysfunction early in the course of the disease. 29, 30, 31, 32 In addition, ACE2 was found in the oral mucosa, notably with an increased concentration mostly over the dorsum of the tongue and salivary glands compared to the buccal or palatal mucosa. 33 Cells with the presence of ACE2 receptors can also become host virus cells and induce inflammatory reactions in associated organs and tissues, such as the mucosa of the tongue and salivary glands.7 Biadsee and colleagues found that 7% of RT-PCR positive patients had plaque-like alterations on the dorsum of the tongue. 33, 34

Diverse orofacial manifestations affiliated with COVID-19 have been reported in a variety of studies. Different types of oral mucosal lesions have been identified by Martín Carreras-Presas et al (ulcer, vesicle, bulla, and desquamative gingivitis) that are clinically similar to several other viral mucocutaneous infections, including herpes simplex, herpes zoster, or immunological disorders. 7, 35, 36

According to a review on oral manifestation published by Iranmanesh et al, the most common sites of involvement in descending order were tongue (38%), labial mucosa (26%), palate (22%), gingiva (8%), buccal mucosa (5%), oropharynx (4%),and tonsil (1%). 33 Because of uncertain treatment options for COVID-19, indirect complex effects, invasive therapeutic methods and multi-drug therapy, SARS-CoV-2 may be anticipated to exacerbate some pathological oral conditions especially in patients with impaired immune systems or who are undergoing long-term pharmacotherapy. 23, 33, 36

It has been documented that oral candida infection almost always involves a locally or systemically compromised host. Taking into consideration that C. albicans is a member of the oral microbiome and that there were desirable events for its pathological growth, such as the decrease in salivation demonstrated in the patient by the sensation of dry mouth, in addition to the repeated use of antibiotics and a minor predisposing factor such as the female sex and the successful response to nystatin treatment, we can clinically confirm candida infection. 10, 37 In our case the white lesion disappeared after 4 days of topical application of nystatin gel. The possibility of fungal co-infections occurring, especially invasive pulmonary aspergillosis in COVID-19 patients, has been discussed in several studies. In addition, COVID-19 patients are also vulnerable to infections caused by the emerging species, C auris, because of many risk factors. 38, 39 Considering the clinical course, disease progression and severity of COVID-19, most of COVID-19 patients with critically ill conditions inevitably experience at least one of following risk factors, for oropharengial candidiasis (OPC), including lymphocytopaenia, ICU admission, invasive or non-invasive ventilation, corticosteroid and broad-spectrum antibiotic usage or having immunocompromised condition which give them a significantly increased

risk for the development of opportunistic fungal infections. 39, 40, 41, 42

A few cases of oral manifestations in patients with COVID-19 have been documented in previous literature, but it is still unclear whether it is the direct action of the virus or the result of systemic degradation that increases the risk of opportunistic injury.

Conclusion

Knowledge of clinical signs and symptoms is crucial for early diagnosis, swift treatment and hence better prognosis. Dental professionals can play a significant role not only in preventing the transmission of COVID-19 but also in the early detection and referral of affected patients. We also propose that rigorous reporting of the clinical scenarios of fungal complications such as oropharyngeal candidiasis may help to clarify the current pandemic and the future role of dentists in frontline teams.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Source of Funding

None.

References

1 

M Najmuddin Journal of Oral Medicine, Oral Surgery, Oral Pathology and OralRadiology20206316

2 

H Tu S Tu S Gao A Shao J Sheng Current epidemiological and clinical features of COVID-19; a global perspective from ChinaJ Infect202081119

3 

F Zhou T Yu R Du G Fan Y Liu Z Liu Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyLancet202039510229105462

4 

T Singhal A Review of Coronavirus Disease-2019 (COVID-19)Indian J Pediatr20208742816

5 

S Recalcati Cutaneous manifestations in COVID-19: a first perspectiveJ Eur Acad Dermatol Venereol2020845e212310.1111/jdv.16387

6 

Y H Jin L Cai Z S Cheng A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)Mil Med Res20207410.1186/s40779-020-0233-6

7 

R O C Tapia A J P Labrador D M Guimaraes L H M Valdez Oral mucosal lesions in patients with SARS-CoV-2 infection. Report of four cases. Are they a true sign of COVID-19 disease?Spec Care Dent20204065556010.1111/scd.12520

8 

Worldmeter Worldmeter [Homepage on the internet] COVID-19 Coronavirus Pandemic. (Accessed July 29, 2020)2020https://www.worldometers.info/coronavirus/.

9 

C Rothe M Schunk P Sothmann Transmission of 2019-nCoV infection from an asymptomatic contact in GermanyN Engl J Med202038210970110.1056/NEJMc2001468

10 

J Corchuelo F C Ulloa Oral manifestations in a patient with a history of asymptomatic COVID-19: Case reportInt J Infect Dis2020100154710.1016/j.ijid.2020.08.071

11 

L Marco Coronavirus disease 2019 in chronic kidney diseaseClinical Kidney J202013329730610.1093/ckj/sfaa104

12 

A Dziedzic R Wojtyczka The impact of coronavirus infectious disease 19 (COVID-19) on oral healthOral Dis2020273703610.1111/odi.13359

13 

M B Fini Oral saliva and COVID-19Oral Oncol202010810482110.1016/j.oraloncology.2020.104821

14 

Yla Kwok J Gralton M-L Mclaws Face touching: a frequent habit that has implications for hand hygieneAm J Infect Control20154321124

15 

J Rubens P Karakousis J Sanjay Stability and viability of SARS-CoV-2N Engl J Med2020382201962310.1056/NEJMc2007942

16 

M B Fini What dentists need to know about COVID-19Oral Oncol202010510474110.1016/j.oraloncology.2020.104741

17 

Z Khurshid F Y Asiri H Al Wadaani Human saliva: non-invasive fluid for detecting novel Coronavirus (SARS-CoV-2)Int J Environ Res Public Health2020177222510.3390/ijerph17072225

18 

H Harapan N Itoh A Yufika W Winardi S Keam H Te Coronavirus disease 2019 (COVID-19): A literature reviewJ Infect Public Health202013566773

19 

L Wang Y Wang D Ye Q Liu Review of the 2019 novel coronavirus (SARS- CoV-2) based on current evidenceInt J Antimicrob Agents202055610594810.1016/j.ijantimicag.2020.105948

20 

H Zhang H B Li J R Lyu X M Lei W Li G Wu Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infectionInt J Infect Dis202096192410.1016/j.ijid.2020.04.027

21 

L Fu B Wang T Yuan Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysisJ Infect20208066566510.1016/j.jinf.2020.03.041

22 

A Riad A Gad B Hockova M Klugar Abanoub Riad et al, Oral candidiasis in non-severe COVID-19 patients: call for antibiotic stewardshipOral Surg202110.1111/ors.12561

23 

M Salehi Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility patternMycoses .2020638771810.1111/myc.13137

24 

J-P Gangneux M-E Bougnoux E Dannaoui M Cornet Z J Ralph Invasive fungal diseases during COVID-19: We should be preparedJ Mycol Med202030210097110.1016/j.mycmed.2020.100971

25 

W-J Guan Z-Y Ni Y U Hu Clinical characteristics of coronavirus disease 2019 in ChinaN Engl J Med202038217082010.1056/NEJMoa2002032

26 

C Huang Y Wang X Li Clinical features of patients infected with 2019 novel coronavirus in Wuhan ChinaLancet202039510223497506

27 

World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (2019-nCoV) infection is suspected: Interim Guidance. 2020. WHO Reference number: WHO/2019- nCoV/clinical2020

28 

A Akpan R Morgan Oral candidiasisPostgrad Med J2002789224559

29 

H Zhang J M Penninger Y Li N Zhong A S Slutsky Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic targetIntensive Care Med20204645869010.1007/s00134-020-05985-9

30 

A Giacomelli L Pezzati F Conti D Bernacchia Mo Siano L Oreni Self-reported Olfactory and Taste Disorders in Patients With Severe Acute Respiratory Coronavirus 2 Infection: A Cross-sectional StudyClin Infect Dis202071158899010.1093/cid/ciaa330

31 

F A C Garcia de Sousa T C Paradella Considerations on oral manifestations of COVID-19J Med Virol2020932667810.1002/jmv.26451

32 

X H Yang W Deng Z Tong Y X Liu L F Zhang H Zhu Mice transgenic from human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infectionComput Med20075754509

33 

B Iranmanesh M Khalili R Amiri H Zartab M Aflatoonian Oral manifestations of COVID-19 disease: A review articleDermatol Ther20203411457810.1111/dth.14578

34 

A Biadsee A Biadsee F Kassem O Dagan S Masarwa Z Ormianer Olfactory and oral manifestations of COVID-19: sex-related symptoms-a potential pathway to early diagnosisOtolaryngol Head Neck Surg202016347228

35 

C M Carreras-Presas J Amaro Sánchez A F López-Sánchez E Jané-Salas M L S Pérez Oral vesiculobullous lesions associated with SARS-CoV-2 infectionOral Dis20202737101210.1111/odi.13382

36 

J A Dos Santos A G C Normando R L Carvalho da Silva A C Acevedo G De Luca Canto N Sugaya Oral Manifestations in Patients with COVID-19: A Living Systematic ReviewJ Dent Res202110021415410.1177/0022034520957289

37 

D J Zegarelli Fungal infections of the oral cavityOtolaryngol Clin North Am1993266106989

38 

A Chowdhary A Sharma The lurking scourge of multidrug resistant Candida auris in times of COVID-19 pandemicJ Glob Antimicrob Resist202022175610.1016/j.jgar.2020.06.003

39 

M Salehi K Ahmadikia S Mahmoudi Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: Species identification and antifungal susceptibility patternMycoses2020638771810.1111/myc.13137

40 

A Riad M Klugar M Krsek COVID-19 related oral manifestations, early disease features?Oral Dis202010.1111/odi.13516

41 

M Salehi K Ahmadikia S Mahmoudi S Kalantari S Jamalimoghadamsiahkali A Izadi Oropharyngeal candidiasis in hospitalised COVID-19 patients from Iran: species identification and antifungal susceptibility patternMycoses2020638771810.1111/myc.13137

42 

R Abanoub A Gad B Hockova M Klugar Letter to the editor Oral candidiasis in non-severe COVID-19 patients: call for antibiotic stewardshipOral Surg202010.1111/ors.12561



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 12-09-2021

Accepted : 30-09-2021


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/ 10.18231/j.idjsr.2021.035


Article Metrics






Article Access statistics

Viewed: 1234

PDF Downloaded: 442